Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis

被引:25
作者
Menezo, V [1 ]
Lau, C [1 ]
Comer, M [1 ]
Lightman, S [1 ]
机构
[1] Moorfields Eye Hosp, Inst Ophthalmol, Dept Clin Ophthalmol, London EC1V 2PD, England
关键词
cyclosporin; macular oedema; methotrexate; mycophenolate; uveitis;
D O I
10.1111/j.1442-9071.2005.00904.x
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aim: To determine the visual outcome and corticosteroid dose requirement in patients with non-infectious uveitis affecting the posterior segment treated with corticosteroids and additional second-line immunosuppression. Method: A retrospective, non-comparative case series was carried out. Seventy-two patients (141 eyes) with uncontrolled non-infectious uveitis on systemic prednisolone were treated with at least one second-line immunosuppressive agent in addition to systemic prednisolone and followed for at least 3 months. Visual acuity (VA), clinical disease activity, corticosteroid-sparing effect, disease relapses requiring corticosteroid dose increase, and side-effects from second-line agents were evaluated. Results: At the end of the follow-up period (mean: 55.5 months), 70 eyes (49.6%) had VA of 6/9 or better. There was a reduction in the mean maintenance dose of prednisolone required before the introduction of the second-line agent (19 mg/day +/- 2 SE) when compared to the mean maintenance dose of prednisolone at the end of the data collection (9 mg/day +/- 1 SF; P < 0.001). There was also a significant reduction in the number of disease relapses requiring an increase in prednisolone dose after starting the second-line agents as compared to the year before (P < 0.02). Conclusion: In patients with uveitis affecting the posterior segment, the addition of all second-line immunosuppressive therapy was effective in allowing reduction of the dose of systemic prednisolone to 10 mg/day or less, in controlling intraocular inflammation, reducing the number of relapses and in maintaining vision. Because of their side-effects, immunosuppressive treatment should be individualized and monitored closely but its addition is beneficial in the short and longer term.
引用
收藏
页码:16 / 21
页数:6
相关论文
共 49 条
  • [1] Aeberli D, 2002, SWISS MED WKLY, V132, P414
  • [2] Successful treatment of serpiginous choroiditis with alkylating agents
    Akpek, EK
    Jabs, DA
    Tessler, HH
    Joondeph, BC
    Foster, CS
    [J]. OPHTHALMOLOGY, 2002, 109 (08) : 1506 - 1513
  • [3] Bernal I, 2003, Gastroenterol Hepatol, V26, P19, DOI 10.1157/13042209
  • [4] Use of methotrexate in the management of sight-threatening uveitis
    Bom, S
    Zamiri, P
    Lightman, S
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2001, 9 (01) : 35 - 40
  • [5] Immunopathology of the noninfectious posterior and intermediate uveitides
    Boyd, SR
    Young, S
    Lightman, S
    [J]. SURVEY OF OPHTHALMOLOGY, 2001, 46 (03) : 209 - 233
  • [6] Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection
    Butani, L
    Palmer, J
    Baluarte, HJ
    Polinsky, MS
    [J]. TRANSPLANTATION, 1999, 68 (01) : 83 - 86
  • [7] CORTICOSTEROIDS AND PEPTIC-ULCER - METAANALYSIS OF ADVERSE EVENTS DURING STEROID-THERAPY
    CONN, HO
    POYNARD, T
    [J]. JOURNAL OF INTERNAL MEDICINE, 1994, 236 (06) : 619 - 632
  • [8] de Maar E F, 2002, Transpl Infect Dis, V4, P17, DOI 10.1034/j.1399-3062.2002.01002.x
  • [9] Methotrexate treatment for sarcoid-associated panuveitis
    Dev, S
    McCallum, RM
    Jaffe, GJ
    [J]. OPHTHALMOLOGY, 1999, 106 (01) : 111 - 118
  • [10] Dick AD, 1998, INVEST OPHTH VIS SCI, V39, P835